Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Alleviating Effect of Active Hexose Correlated Compound (AHCC) on Chemotherapy-Related Adverse Events in Patients with Unresectable Pancreatic Ductal Adenocarcinoma.

Yanagimoto H, Satoi S, Yamamoto T, Hirooka S, Yamaki S, Kotsuka M, Ryota H, Michiura T, Inoue K, Matsui Y, Tsuta K, Kon M.

Nutr Cancer. 2016;68(2):234-40. doi: 10.1080/01635581.2016.1134597. Epub 2016 Feb 4.

PMID:
26847832
2.

[Modern possibilities of chemotherapy in patients with ductal pancreatic adenocarcinoma].

Kopchak VM, Kopchak KV, Romaniv IaV.

Klin Khir. 2006 Feb;(2):23-5. Russian.

PMID:
16826811
3.

[A Case Report of Curative Surgery for Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination after Gemcitabine Chemotherapy].

Ichikawa Y, Yamada D, Eguchi H, Iwagami Y, Noda T, Asaoka T, Wada H, Kawamoto K, Gotoh K, Kobayashi S, Tatsumi M, Takeyari M, Mori M, Doki Y.

Gan To Kagaku Ryoho. 2017 Nov;44(12):2014-2016. Japanese.

PMID:
29394852
4.

Active hexose-correlated compound down-regulates HSP27 of pancreatic cancer cells, and helps the cytotoxic effect of gemcitabine.

Suenaga S, Kuramitsu Y, Kaino S, Maehara S, Maehara Y, Sakaida I, Nakamura K.

Anticancer Res. 2014 Jan;34(1):141-6.

PMID:
24403454
5.

Gemcitabine as first-line chemotherapy in elderly patients with unresectable pancreatic carcinoma.

Yamagishi Y, Higuchi H, Izumiya M, Sakai G, Iizuka H, Nakamura S, Adachi M, Hozawa S, Takaishi H, Hibi T.

J Gastroenterol. 2010 Nov;45(11):1146-54. doi: 10.1007/s00535-010-0258-9. Epub 2010 Jun 15.

PMID:
20549255
6.

Efficacy and safety of metallic stents in patients with unresectable pancreatic cancer receiving gemcitabine.

Nakai Y, Isayama H, Kawabe T, Tsujino T, Yoshida H, Sasaki T, Tada M, Arizumi T, Yagioka H, Kogure H, Togawa O, Ito Y, Matsubara S, Hirano K, Sasahira N, Omata M.

Pancreas. 2008 Nov;37(4):405-10. doi: 10.1097/MPA.0b013e3181706d93.

PMID:
18953253
7.

Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP).

Fensterer H, Schade-Brittinger C, Müller HH, Tebbe S, Fass J, Lindig U, Settmacher U, Schmidt WE, Märten A, Ebert MP, Kornmann M, Hofheinz R, Endlicher E, Brendel C, Barth PJ, Bartsch DK, Michl P, Gress TM; Arbeitsgemeinschaft Internistische Onkologie.

Ann Oncol. 2013 Oct;24(10):2576-81. doi: 10.1093/annonc/mdt270. Epub 2013 Jul 29.

PMID:
23897705
8.
9.

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer.

Dalgleish AG, Stebbing J, Adamson DJ, Arif SS, Bidoli P, Chang D, Cheeseman S, Diaz-Beveridge R, Fernandez-Martos C, Glynne-Jones R, Granetto C, Massuti B, McAdam K, McDermott R, Martín AJ, Papamichael D, Pazo-Cid R, Vieitez JM, Zaniboni A, Carroll KJ, Wagle S, Gaya A, Mudan SS.

Br J Cancer. 2016 Sep 27;115(7):789-96. doi: 10.1038/bjc.2016.271. Epub 2016 Sep 6. Erratum in: Br J Cancer. 2016 Oct 25;115(9):e16.

10.

Chemotherapy-induced neutropenia as a prognostic factor in patients with unresectable pancreatic cancer.

Kurihara T, Kogo M, Ishii M, Shimada K, Yoneyama K, Kitamura K, Shimizu S, Yoshida H, Kiuchi Y.

Cancer Chemother Pharmacol. 2015 Dec;76(6):1217-24. doi: 10.1007/s00280-015-2887-4. Epub 2015 Nov 11.

PMID:
26560484
11.

Survival variability of controls and definition of imaging endpoints for longitudinal follow-up of pancreatic ductal adenocarcinoma in rats.

Akladios C, Ignat M, Mutter D, Aprahamian M.

J Cancer Res Clin Oncol. 2017 Jan;143(1):29-34. doi: 10.1007/s00432-016-2265-6. Epub 2016 Sep 12.

PMID:
27620742
12.

Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts.

Waters JA, Matos J, Yip-Schneider M, Aguilar-Saavedra JR, Crean CD, Beane JD, Dumas RP, Suvannasankha A, Schmidt CM.

Surgery. 2015 Oct;158(4):881-8; discussion 888-9. doi: 10.1016/j.surg.2015.04.043. Epub 2015 Jul 21.

PMID:
26209568
13.

[Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCD/SFRO phase III trial].

Barhoumi M, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouché O, Bosset JF, Aparicio T, Mineur L, Azzedine A, Hammel P, Butel J, Stremsdoerfer N, Maingon P, Bedenne L, Chauffert B.

Cancer Radiother. 2011 Jun;15(3):182-91. doi: 10.1016/j.canrad.2010.10.001. Epub 2011 Feb 10. French.

PMID:
21315644
14.

The Glasgow Prognostic Score is a good predictor of treatment outcome in patients with unresectable pancreatic cancer.

Shimoda M, Katoh M, Kita J, Sawada T, Kubota K.

Chemotherapy. 2010;56(6):501-6. doi: 10.1159/000321014. Epub 2010 Nov 24.

PMID:
21099223
15.

[Clinical study of gemcitabine therapy for recurrent or metastatic pancreatic cancer].

Moriwaki T, Hyodo I, Nishina T, Nasu J, Hidaka S, Kajiwara T, Tsuzuki T, Hirao K, Tsubouchi E, Yamauchi Y, Hirasaki S, Masumoto T, Tanada M.

Gan To Kagaku Ryoho. 2004 Sep;31(9):1373-6. Japanese.

PMID:
15446559
16.

Prognostic value of altered N-glycosylation of circulating glycoproteins in patients with unresectable pancreatic cancer treated with gemcitabine.

Miyahara K, Nouso K, Morimoto Y, Kinugasa H, Kato H, Yamamoto N, Tsutsumi K, Kuwaki K, Onishi H, Ikeda F, Nakamura S, Shiraha H, Takaki A, Nakahara T, Miura Y, Asada H, Amano M, Nishimura S, Yamamoto K.

Pancreas. 2015 May;44(4):551-6. doi: 10.1097/MPA.0000000000000321.

PMID:
25875794
17.

Analysis of second-line chemotherapies for ductal pancreatic adenocarcinoma in a German single-center cohort.

Maier-Stocker C, Bitzer M, Malek NP, Plentz RR.

Scand J Gastroenterol. 2014 Dec;49(12):1480-5. doi: 10.3109/00365521.2014.978816. Epub 2014 Nov 12.

PMID:
25390691
18.

Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.

Loehrer PJ Sr, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, Flynn P, Ramanathan RK, Crane CH, Alberts SR, Benson AB 3rd.

J Clin Oncol. 2011 Nov 1;29(31):4105-12. doi: 10.1200/JCO.2011.34.8904. Epub 2011 Oct 3.

19.

Circulating regulatory T cell subsets predict overall survival of patients with unresectable pancreatic cancer.

Liu C, Cheng H, Luo G, Lu Y, Jin K, Guo M, Ni Q, Yu X.

Int J Oncol. 2017 Aug;51(2):686-694. doi: 10.3892/ijo.2017.4032. Epub 2017 Jun 7.

PMID:
28714519
20.

Effect of active hexose-correlated compound in women receiving adjuvant chemotherapy for breast cancer: a retrospective study.

Hangai S, Iwase S, Kawaguchi T, Kogure Y, Miyaji T, Matsunaga T, Nagumo Y, Yamaguchi T.

J Altern Complement Med. 2013 Nov;19(11):905-10. doi: 10.1089/acm.2012.0914. Epub 2013 Jul 5.

Supplemental Content

Support Center